Case Study: Fuse Vectors achieves end-to-end traceability for AAV development with Benchling

Revolutionizing gene therapy by redefining AAV development status quo

Fuse Vectors is a biotech startup working to revolutionize gene therapy with its cell-free viral vector technology for AAV development. As the team grew, its reliance on Excel, Geneious, and home-grown software created data silos, making it harder to capture and manage information across assays, plasmids, proteins, and samples. To solve this, Fuse Vectors turned to Benchling and its platform for data capture and management.

Benchling implemented an end-to-end traceability system that gave Fuse Vectors better visibility into its R&D workflow and more reliable data management. The result was a clearer high-level view for managers and leadership, helping reduce the gaps created by fragmented tools and supporting faster, more scalable gene therapy development.

Fuse Vectors